Mersana Therapeutics (NASDAQ: MRSN) reported Q4 EPS of ($0.44), $0.05 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $14.69 million versus the consensus estimate of $15.28 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.